Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
作者： Benjamin J. Solomon , Elizabeth E. Kim , Maria Winter , Katherine Monti , Yiyun Tang
DOI: 10.1016/J.LUNGCAN.2020.04.010
关键词: Lung cancer 、 Intraocular pressure 、 Fundus photography 、 Context (language use) 、 Crizotinib 、 Discontinuation 、 Ophthalmology 、 Medicine 、 Visual acuity 、 Refractive error
摘要: … should continue their regular ophthalmic eye care while on crizotinib therapy and for those patients who develop ocular symptoms in the context of ongoing crizotinib treatment, an …
sci-hub.st 参考文章(11)
Alice T. Shaw, Sai-Hong I. Ou, Yung-Jue Bang, D. Ross Camidge, Benjamin J. Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella-Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, Lesley M. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate, Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 371, pp. 1963- 1971 ,(2014) , 10.1056/NEJMOA1406766
Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D Wilner, Jennifer Tursi, Fiona Blackhall, None, First-line crizotinib versus chemotherapy in ALK-positive lung cancer The New England Journal of Medicine. ,vol. 371, pp. 2167- 2177 ,(2014) , 10.1056/NEJMOA1408440
Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate, Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 363, pp. 1693- 1703 ,(2010) , 10.1056/NEJMOA1006448
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim, Ravi Salgia, Panagiotis Fidias, Jeffrey A Engelman, Leena Gandhi, Pasi A Jänne, Daniel B Costa, Geoffrey I Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith Wilner, Jeffrey W Clark, Alice T Shaw, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncology. ,vol. 13, pp. 1011- 1019 ,(2012) , 10.1016/S1470-2045(12)70344-3
Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Meera Tugnait, Narayana I Narasimhan, David J Dorer, David Kerstein, Victor M Rivera, Timothy Clackson, Frank G Haluska, David Ross Camidge, Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial The Lancet Oncology. ,vol. 17, pp. 1683- 1696 ,(2016) , 10.1016/S1470-2045(16)30392-8
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Koichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Takashi Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura, None, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial The Lancet. ,vol. 390, pp. 29- 39 ,(2017) , 10.1016/S0140-6736(17)30565-2
Alice T Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok, Makoto Nishio, Giorgio Scagliotti, David R Spigel, Stéphanie Deudon, Cheng Zheng, Serafino Pantano, Patrick Urban, Cristian Massacesi, Kalyanee Viraswami-Appanna, Enriqueta Felip, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial Lancet Oncology. ,vol. 18, pp. 874- 886 ,(2017) , 10.1016/S1470-2045(17)30339-X
Fiona Blackhall, D Ross Camidge, Alice T Shaw, Jean-Charles Soria, Benjamin J Solomon, Tony Mok, Vera Hirsh, Pasi A Jänne, Yuankai Shi, Pan-Chyr Yang, Tommaso De Pas, Toyoaki Hida, Javier De Castro Carpeño, Silvana Lanzalone, Anna Polli, Shrividya Iyer, Arlene Reisman, Keith D Wilner, Dong-Wan Kim, Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO open. ,vol. 2, ,(2017) , 10.1136/ESMOOPEN-2017-000219
Manuela Schmidinger, Romano Danesi, Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma Oncologist. ,vol. 23, pp. 306- 315 ,(2018) , 10.1634/THEONCOLOGIST.2017-0335